Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$380,154 Mln
P/E Ratio
17.55
P/B Ratio
5.24
Industry P/E
--
Debt to Equity
0.51
ROE
0.2 %
ROCE
13.64 %
Div. Yield
3.3 %
Book Value
29.45
EPS
5.8
CFO
$214,121.00 Mln
EBITDA
$225,943.00 Mln
Net Profit
$168,674.00 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Johnson & Johnson (JNJ)
| 6.89 | -5.33 | 5.29 | 4.07 | -5.22 | -0.04 | 4.34 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P 100
| -7.84 | -4.23 | -10.10 | 11.63 | 11.27 | 15.45 | 11.18 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Johnson & Johnson (JNJ)
| -7.67 | -11.27 | 3.26 | 8.70 | 7.89 | 13.03 | -7.60 |
|
S&P 100
| 29.04 | 30.83 | -22.12 | 27.55 | 19.30 | 29.47 | -5.82 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 186.06 | 313,197.92 | 74.08 | 62.52 | |
| 280.84 | 149,681.93 | 36.76 | 67.55 | |
| 884.54 | 794,307.13 | 75.67 | 84.41 | |
| 82.74 | 198,719.28 | 11.68 | 40.81 |
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative... Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey. Address: One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933 Read more
CEO & Chairman
Mr. Joaquin Duato
CEO & Chairman
Mr. Joaquin Duato
Headquarters
New Brunswick, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Johnson & Johnson (JNJ) stood at -- as on 31-Dec-24
The share price of Johnson & Johnson (JNJ) is $154.58 (NYSE) as of 25-Apr-2025 16:12 EDT. Johnson & Johnson (JNJ) has given a return of -5.22% in the last 3 years.
Johnson & Johnson (JNJ) has a market capitalisation of $ 380,154 Mln as on 24-Apr-2025. As per Value Research classification, it is a Large Cap company.
The P/E ratio of Johnson & Johnson (JNJ) is 17.55 times as on 24-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Johnson & Johnson (JNJ) and enter the required number of quantities and click on buy to purchase the shares of Johnson & Johnson (JNJ).
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey. Address: One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933
The CEO & director of Mr. Joaquin Duato. is Johnson & Johnson (JNJ), and CFO & Sr. VP is Mr. Joaquin Duato.
There is no promoter pledging in Johnson & Johnson (JNJ).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
74,481
|
|
|
31,320
|
|
|
19,872
|
|
|
14,968
|
| Johnson & Johnson (JNJ) | Ratios |
|---|---|
|
Return on equity(%)
|
20.06
|
|
Operating margin(%)
|
19.64
|
|
Net Margin(%)
|
15.84
|
|
Dividend yield(%)
|
--
|
Yes, TTM profit after tax of Johnson & Johnson (JNJ) was $14,066 Mln.
$-0.35
(
